|
Congressional:
House Republicans Continue Work on Medicaid Proposals in Reconciliation Package
On Tuesday, Speaker Mike Johnson (R-LA) met with other Republican leaders in a closed-door meeting to discuss Medicaid options in the upcoming reconciliation bill. Following the meeting, Johnson stated that the emerging package would not affect the Federal Medical Assistance Percentage (FMAP) rate for the Medicaid expansion population, which is currently set at 90 percent. Johnson also indicated that the bill would likely not include per capita caps on Medicaid benefits for enrollees in expansion states, saying, "I think we're ruling that out as well, but stay tuned." Additionally. Johnson noted that the bill would include new work requirements for healthy adults in states that expanded Medicaid to receive the 90 percent federal match. However, it is likely that savings from the current proposals under consideration could achieve much higher savings over the ten-year budget window. Other members in the meeting said a policy the Trump administration has pushed as an alternative to the steep Medicaid cuts, linking what the program pays for drugs to the lower prices paid abroad, also was not a current focus for inclusion in the bill at this time.
Senate Finance Committee Holds Nomination Hearing for James O’Neill and Gary Andres
On Tuesday, the Senate Finance Committee held a hearing to consider the nominations of James O'Neill to be Deputy Secretary of Health and Human Services (HHS) and Gary Andres to be an Assistant Secretary at HHS. During the hearing, Republicans appeared confident that O’Neill and Andres have the experience to take on the roles. Democrats asked several questions related to HHS Secretary Robert Kennedy Jr., inquiring whether O’Neill agreed with or would push back on Kennedy’s more controversial statements. O’Neill did not criticize any of Kennedy’s recent statements or actions but repeatedly stated that he had received the MMR vaccine. Ranking Member Wyden (D-OR) and other Democrats also asked for commitments that the nominees would respect congressional oversight and inquiries into how HHS is responding to health crises, reorganizing the department, or cutting health programs. Senator Bill Cassidy (R-LA) also sought answers related to Kennedy’s agency reorganization plans, stating, “I don't mean to challenge, but you're so talented, it does seem as if we do have an issue. I'm trying to learn if critical functions are being not met.”
Senate HELP Committee Holds Hearing on James O’Neill Nomination
On Thursday, the Senate Health, Education, Labor, and Pensions (HELP) Committee also held a hearing to consider the nomination of James O'Neill. During the hearing, Chair Bill Cassidy (R-LA), asked O'Neill whether he thought people seeking residency in the United States should be required to be up to date on their immunizations, to which O’Neill answered, "I haven't looked into the immigration law aspect of this but I do support the CDC schedule and that rule seems reasonable to me.” On gain-of-function research, O'Neill said that regulation might be appropriate, but that regulation often struggles to keep pace with technological advancements. He stated he would like to recruit "very excellent" technologists to assist with gain-of-function research. Senator Angela Alsobrooks (D-MD), filling in for Ranking Member Bernie Sanders (I-VT), stated, "We need a deputy secretary of Health and Human Services who will fight to continue health care as a human right, not a privilege, regardless of whether you are poor, working class, or wealthy.”
26 Members of Congress Advocate for Changes to Drug Price Negotiation Program to Protect Pharmacies
On Tuesday, a bipartisan group of 26 Representatives, led by Representatives Buddy Carter (R-GA) and Jake Auchincloss (D-MA), sent a letter to Secretary of Health and Human Services (HHS) Robert F. Kennedy, Jr., and Mehmet Oz, Administrator of the Centers for Medicare & Medicaid Services (CMS), outlining their concerns about the implementation of the Inflation Reduction Act's Medicare Drug Price Negotiation Program and its effects on pharmacies. In the letter, the members stated that the current implementation pathway for the Medicare Drug Price Negotiation Program is unsustainable for pharmacies by forcing them to purchase drugs at higher prices and then wait to be paid back and made whole again. “In other words, pharmacies will have to provide a financial float for the very MFP refund they will receive, to the detriment of thousands of dollars a week per pharmacy which compounds into tens of thousands of dollars lost in annual revenue for each store,” the members wrote. Read the letter here.
Notable Bills Introduced:
Senators Cortez Masto, Collins Reintroduce Bipartisan Legislation to Protect and Enhance Ground Ambulance Services
On Thursday, Senators Catherine Cortez Masto (D-NV), Susan Collins (R-ME), Bill Cassidy (R-LA), and Peter Welch (D-VT) introduced the bipartisan Protecting Access to Ground Ambulance Medical Services Act, which would ensure that communities have access to emergency and non-emergency ground ambulance services through extending and increasing Medicare add-on payments for ambulance services. Read the press release here and the bill here.
Senators Hawley & Welch Introduce Legislation to Lower Prescription Drug Prices
On Monday, Senators Josh Hawley (R-MO) and Peter Welch (D-VT) introduced the Fair Prescription Drug Prices for Americans Act. The legislation would prohibit pharmaceutical companies from selling drugs in the U.S. at higher prices than the international average. It would also impose civil monetary penalties on pharmaceutical companies that violate this rule. Specifically, the penalty would equal 10 times the difference between the U.S. list price and the average price of the drug sold in Canada, France, Germany, Japan, Italy, and the United Kingdom. Penalties would be calculated and charged for each unit of drug or biological product sold at an inflated price. Read the press release here and the bill here.
Senators Luján, Murkowski Reintroduce Bipartisan Legislation to Combat Maternal and Infant Mortality Crisis
On Monday, Senators Ben Ray Luján (D-NM) and Lisa Murkowski (R-AK) reintroduced the Midwives for Maximizing Optimal Maternity Services (MOMS) Act, bipartisan legislation that addresses the maternal and infant mortality crisis by increasing the number of trained midwives in the United States. The bipartisan legislation would increase funding for midwifery education and increase diversity in the maternity care workforce by recruiting students from minority or disadvantaged backgrounds. Read the press release here and the bill here.
Representatives Dean, Miller-Meeks, and Senators Hyde-Smith, King Reintroduce Bipartisan, Bicameral Bill to Protect Healthcare Workers
On Monday, Representatives Madeleine Dean (D-PA) and Mariannette Miller-Meeks (R-IA) introduced the Save Healthcare Workers Act, which would create legal penalties for individuals who knowingly and intentionally assault hospital employees. This bipartisan legislation mirrors current protections for aircraft and airport workers, like flight crews and attendants. Senators Cindy Hyde-Smith (R-MS) and Angus King (I-ME) are leading companion legislation in the Senate. Read the press release here and the bill here.
Representative Arrington Introduces Bipartisan Emergency Care Improvement Act
On Monday, House Budget Chairman Jodey Arrington (R-TX) and Representative Vicente Gonzalez (D-TX) introduced the Emergency Care Improvement Act. The legislation would permanently expand access to emergency medical care for Medicare, Tricare, and Medicaid beneficiaries. Read the press release here and the bill here.
Senators Wicker, Merkley Introduce Bipartisan Nurse Corps Tax Parity Act
Late last week, on Friday, Senators Roger Wicker (R-MS) and Jeff Merkley (D-OR), Co-Chairs of the Senate Nursing Caucus, introduced the Nurse Corps Tax Parity Act. The legislation would ensure that nurses in the federal Nurse Corps do not need to pay income tax on their student loan repayments and scholarships. Read the press release here and the bill here.
Representatives Smith, Schneider, Harshbarger, Matsui, Reintroduce Bipartisan Bill to Expand Seniors' Healthcare Options
Late last week, on Friday, Representatives Adrian Smith (R-NE), Brad Schneider (D-IL), Diana Harshbarger (R-TN), and Doris Matsui (D-CA) introduced the Ensuring Community Access to Pharmacist Services Act. The bill would provide for Medicare coverage of pharmacist-administered tests for common respiratory illnesses, such as influenza, respiratory syncytial virus (RSV), strep throat, and COVID-19. It would also allow pharmacists to prescribe treatments for these illnesses when properly indicated. Read the press release here and the bill here.
Executive Branch:
Trump Withdraws Janette Nesheiwat and Nominates Casey Means as Surgeon General
On Wednesday, President Trump withdrew Janette Nesheiwat’s nomination to be Surgeon General, a day before the Senate Health, Education, Labor and Pensions Committee was scheduled to hold a hearing on Nesheiwat’s nomination. On the same day, Trump announced he had nominated Casey Means to be Surgeon General via Truth Social. Casey Means is the sister of Calley Means, a top aide to Health and Human Services Secretary Robert F. Kennedy Jr. Casey Means received a medical degree from Stanford Medical School, but left residency during her training as a surgeon. She later co-founded Levels Health, a subscription-based app backed by venture firm a16z that connects users to wearable glucose monitors. Last year, the Means siblings published a book, "Good Energy: The Surprising Connection Between Metabolism and Limitless Health." In his post, Trump stated that “Casey has impeccable ‘MAHA’ credentials.” In the same post, Trump also said that Nesheiwat will serve HHS in "another capacity."
Trump Announces Actions to Reduce Regulatory Barriers to Domestic Pharmaceutical Manufacturing
On Monday, President Trump signed an executive order (EO) titled "Regulatory Relief to Promote Domestic Production of Critical Medicines," aimed at strengthening the U.S. pharmaceutical supply chain by reducing regulatory barriers. The order directs the Food and Drug Administration (FDA) to review and streamline existing regulations to expedite the approval process for domestic pharmaceutical manufacturing facilities, including those utilizing emerging technologies. Additionally, it mandates the FDA to enhance inspections of foreign manufacturing sites and consider publicly disclosing non-compliant facilities, while the Environmental Protection Agency (EPA) is instructed to update regulations to facilitate the timely construction and expansion of pharmaceutical manufacturing capacity. Read the EO here and the fact sheet here.
Trump Issues Executive Order to Ban Gain-Of-Function Research
On Monday, President Trump signed an executive order (EO) aimed at enhancing the safety and security of biological research. The order terminates all current and future federal funding for gain-of-function research in countries with inadequate oversight, such as China and Iran, and empowers U.S. agencies to identify and halt funding for other biological research that could threaten public health or national security. It also suspends certain domestic research involving infectious pathogens until a more robust oversight policy is developed, mandating the Office of Science and Technology Policy and the National Security Advisor to establish new guidelines within 120 days. The White House fact sheet stated the order “will drastically reduce the potential for lab-related incidents involving gain-of-function research, like that conducted on bat coronaviruses in China by the EcoHealth Alliance and Wuhan Institute of Virology.” Read the EO here and the fact sheet here.
FDA Announces Completion of First AI-Assisted Scientific Review Pilot and Aggressive Agency-Wide AI Rollout Timeline
On Thursday, Food and Drug Administration (FDA) Commissioner Martin Makary announced an aggressive timeline to scale the use of artificial intelligence (AI) internally across all FDA centers by June 30, 2025, following the completion of a new generative AI pilot for scientific reviewers. Makary has directed all FDA centers to begin deployment immediately, with the goal of full integration by the end of June. Work will continue to expand use cases, improve functionality and adapt to the evolving needs of each center after June 30. By that date, the FDA announcement stated that all centers will be operating on a common, secure generative AI system integrated with FDA’s internal data platforms. Read the press release here.
FDA Names New Top Vaccine Regulator
On Tuesday, Food and Drug Administration (FDA) Commissioner Marty Makary announced that Dr. Vinay Prasad would lead the Center for Biologics Evaluation and Research after Dr. Peter Marks resigned in March. Prasad is a professor of epidemiology and biostatistics at the University of California, San Francisco. Prasad gained popularity on X during the pandemic, criticizing the public health response. While he’s endorsed the COVID-19 shot’s efficacy, he has criticized mandating it. Makary wrote in his post that, "With 500+ peer-reviewed publications and two books, Dr. Prasad brings the kind of scientific rigor, independence, and transparency we need at CBER--a significant step forward."
FDA Appoints First Chief AI Officer
Late last week, on Friday, the Food and Drug Administration (FDA) appointed Jeremy Walsh as Chief Officer of Artificial Intelligence (AI) and Information Technology in a newly created position. Previously, Walsh worked as a government contractor for Booz Allen Hamilton, where he spent 14 years as chief technologist, building cloud networks and data analytics systems for the agencies the firm supports. While at Booz Allen, Walsh worked on contracts with the FDA, the Centers for Disease Control and Prevention (CDC), the National Institutes of Health (NIH), the Department of Veterans Affairs, and military health services.
Secretary Kennedy Asks CDC to Search for New Measles Treatments
Late last week, a Health and Human Services (HHS) spokesperson said that HHS Secretary Robert F. Kennedy Jr. is directing the agency to develop new therapies to treat measles infection for people who decide not to get the measles, mumps and rubella vaccine. The spokesperson stated that, “Secretary Kennedy will be enlisting the entire Department to activate a scientific process to treat a host of diseases, including measles, with single or multiple existing drugs in combination with vitamins and other modalities.” They added that, “This process will work collaboratively with universities across the country to develop protocols, testing and approval of new therapeutics that are safe and effective and meet the highest standards of science.”
Legal & Other:
States Sue Trump Administration Over Widespread HHS Firings
On Monday, 20 attorneys general, led by New York Attorney General Letitia James and 18 other Democratic-appointed attorneys general from around the country, filed a lawsuit in the U.S. District Court for the District of Rhode Island, challenging the Trump administration's staffing reductions at the Department of Health and Human Services (HHS). The lawsuit argues that the department has violated the law by gutting entities that were mandated by Congress, including drastic staffing reductions at the National Institute for Occupational Safety and Health and the National Center Chronic Disease Prevention and Health Promotion. "This administration is not streamlining the federal government; they are sabotaging it and all of us," James said in a statement. "When you fire the scientists who research infectious diseases, silence the doctors who care for pregnant patients, and shut down the programs that help firefighters and miners breathe or children thrive, you are not making America healthy -- you are putting countless lives at risk." The states are asking the court to declare the actions unlawful and vacate them. An HHS spokesperson said in a statement to that the department is following the law and that the process has not been rushed. "Every step taken has been deliberate, collaborative, and consistent with federal personnel policy and civil service protections. To suggest otherwise is inaccurate and misrepresents the integrity and facts of the process," the spokesperson said. The case is New York v. Kennedy.
|